Solid Biosciences Inc.

Solid Biosciences is a precision genetic medicine company developing gene therapy candidates for rare neuromuscular and cardiac diseases. Its pipeline includes programs for Duchenne muscular dystrophy, Friedreich’s ataxia, catecholaminergic polymorphic ventricular tachycardia, and genetic cardiomyopathies. The company also develops genetic regulators and other enabling technologies intended to improve gene-therapy delivery. Founded by people directly affected by Duchenne, its mission is to improve daily life for patients with rare diseases.